# A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

Source: https://onco.cc/trials/nct06833008/  
OnCo record `nct06833008` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of IPN01195 in advanced solid tumours, run by Ipsen, now recruiting.

## Summary

A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours is a phase 1/2 interventional study registered as NCT06833008 by Ipsen, with 85 participants planned, started 2025-03-14 and due to reach its primary completion in 2028-10-03. Interventions recorded: IPN01195.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06833008
- Phase: 1/2
- Setting: An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours
- Sponsor: Ipsen
- Enrolled: 85

## Sources

- ClinicalTrials.gov NCT06833008: https://clinicaltrials.gov/study/NCT06833008

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Ipsen](https://onco.cc/companies/ipsen/)

---
JSON: https://onco.cc/api/v1/entities/nct06833008.json